Skip to main navigation Skip to search Skip to main content

Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE

  • the GARFIELD-VTE investigators
  • University of Insubria
  • Sheba Medical Center
  • Tel Aviv University
  • Thrombosis Research Institute
  • McMaster University
  • McMaster University and the Thrombosis and Atherosclerosis Research Institute
  • Formerly Technical University of Munich
  • Tokai University School of Medicine
  • Harvard Medical School
  • Alfred Hospital
  • Municipal Hospital Dresden
  • University of Geneva
  • IRCCS Multimedica
  • University of Milan
  • Arianna Foundation on Anticoagulation

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

Background: Inferior vena cava (IVC) thrombosis is a rare form of venous thromboembolism (VTE). The optimal treatment strategies and outcomes are unclear in patients with this presentation. Objective: We aimed to compare baseline characteristics, treatment patterns and 24-month outcomes in IVC thrombosis patients (n = 100) with lower extremity deep vein thrombosis (LEDVT) patients (n = 7629). Methods: GARFIELD–VTE is a prospective, observational registry of 10 868 patients with objectively diagnosed VTE from 415 sites in 28 countries. Results: IVC thrombosis patients were younger (51.9 vs. 59.8 years), more frequently had active cancer (26.0% vs. 8.9%) or history of cancer (21.0% vs. 12.2%), and less frequently had recent trauma or surgery than LEDVT patients. IVC thrombosis was more frequently treated with parenteral anticoagulants alone (35.1% vs. 15.9%), whereas patients with LEDVT more commonly received vitamin K antagonists (32.0% vs. 25.8%) or direct oral anticoagulants (49.0% vs. 35.1%). Thrombolysis (11.0% vs. 3.6%) and surgical/mechanical interventions (4.0% vs. 1.4%) were more frequent in IVC thrombosis. At 24-months, the rate per 100 person-years (95% confidence interval) of all-cause mortality was higher in patients with IVC thrombosis than LEDVT (13.28 [8.57–20.58] vs. 4.91 [4.55–5.3]); the incidence of cancer-associated mortality was comparable as was the incidence of VTE recurrence (4.11 [1.85–9.15] vs. 4.18 [3.84–4.55]). Major bleeding was slightly higher in IVC thrombosis (2.03 [0.66–6.31] vs. 1.66 [1.45–1.89]). Conclusion: In summary, IVC thrombosis patients have higher all-cause mortality rates than those with LEDVT, a finding only partly attributable to malignancy.

Original languageEnglish
Pages (from-to)366-374
Number of pages9
JournalJournal of Thrombosis and Haemostasis
Volume20
Issue number2
DOIs
Publication statusPublished - Feb 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE'. Together they form a unique fingerprint.

Cite this